drugset / Trial / NCT07532408
Romiplostim N01 in the Treatment of Refractory Chemoradiotherapy-induced AA
NaSingle-groupOpen-labelTreatment
Summary
This study aimed to explore the efficacy and safety of romiplostim N01 in the treatment of relapsed/refractory chemoradiotherapy-induced aplastic anemia
Timeline
- Start
- 2026-06
- Primary completion
- 2028-12
- Completion
- 2029-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Romiplostim N01 | Peptide | 20 ug/kg | Subcutaneous |